Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Junshi Biosciences
Biotech
Fosun pays $32M to join Lilly and Novartis in psoriasis market
A Fosun Pharma subsidiary has paid Junshi Biosciences $32 million for Chinese rights to a near-approval autoimmune disease drug candidate.
Nick Paul Taylor
Jul 2, 2026 8:30am
Junshi sees ph. 3 psoriasis win for IL-17 drug, preps China push
Sep 8, 2025 4:54am
Coherus axes TIGIT program 2 years after making $35M bet
Jan 10, 2024 7:50am
Junshi's Lynparza rival hits mark in ovarian cancer phase 3
Apr 12, 2023 5:30am
Junshi data tee up challenge to Amgen, Sanofi in growth market
Feb 28, 2023 2:00am
I-Mab, Junshi's cancer combo worked best as first-line treatment
May 26, 2022 5:00pm
